Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.51 Million USD | 26.75% |
| 2022 | 13.02 Million USD | 389.74% |
| 2021 | 2.66 Million USD | 94.87% |
| 2020 | 1.36 Million USD | -22.4% |
| 2019 | 1.75 Million USD | 7.91% |
| 2018 | 1.63 Million USD | -63.42% |
| 2017 | 4.45 Million USD | -19.26% |
| 2016 | 5.51 Million USD | 22.94% |
| 2015 | 4.48 Million USD | 626.29% |
| 2014 | 618.07 Thousand USD | -7.77% |
| 2013 | 670.15 Thousand USD | 2.82% |
| 2012 | 651.75 Thousand USD | -1.07% |
| 2011 | 658.77 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 13.71 Million USD | -16.95% |
| 2024 Q2 | 19.98 Million USD | 45.72% |
| 2023 Q4 | 16.51 Million USD | 25.94% |
| 2023 Q2 | 14.74 Million USD | 5.8% |
| 2023 Q3 | 13.11 Million USD | -11.11% |
| 2023 FY | 16.51 Million USD | 26.75% |
| 2023 Q1 | 13.94 Million USD | 7.01% |
| 2022 FY | 13.02 Million USD | 389.74% |
| 2022 Q2 | 11.39 Million USD | 152.83% |
| 2022 Q3 | 13.14 Million USD | 15.37% |
| 2022 Q4 | 13.02 Million USD | -0.91% |
| 2022 Q1 | 4.5 Million USD | 69.44% |
| 2021 Q1 | 1.31 Million USD | -4.03% |
| 2021 FY | 2.66 Million USD | 94.87% |
| 2021 Q4 | 2.66 Million USD | 98.66% |
| 2021 Q3 | 1.33 Million USD | -3.88% |
| 2021 Q2 | 1.39 Million USD | 6.34% |
| 2020 Q1 | 1.41 Million USD | -19.73% |
| 2020 Q3 | 1.93 Million USD | 12.43% |
| 2020 Q2 | 1.72 Million USD | 21.95% |
| 2020 Q4 | 1.36 Million USD | -29.49% |
| 2020 FY | 1.36 Million USD | -22.4% |
| 2019 Q4 | 1.75 Million USD | 22.92% |
| 2019 Q1 | 2.49 Million USD | 53.31% |
| 2019 FY | 1.75 Million USD | 7.91% |
| 2019 Q2 | 1.45 Million USD | -41.74% |
| 2019 Q3 | 1.43 Million USD | -1.72% |
| 2018 Q3 | 1.48 Million USD | 3.19% |
| 2018 Q4 | 1.63 Million USD | 9.62% |
| 2018 FY | 1.63 Million USD | -63.42% |
| 2018 Q1 | 4.14 Million USD | -6.98% |
| 2018 Q2 | 1.44 Million USD | -65.24% |
| 2017 Q4 | 4.45 Million USD | 22.69% |
| 2017 Q2 | 2.83 Million USD | 6.07% |
| 2017 Q1 | 2.67 Million USD | -51.6% |
| 2017 FY | 4.45 Million USD | -19.26% |
| 2017 Q3 | 3.63 Million USD | 28.2% |
| 2016 Q1 | 4.95 Million USD | 10.43% |
| 2016 FY | 5.51 Million USD | 22.94% |
| 2016 Q2 | 4.78 Million USD | -3.51% |
| 2016 Q4 | 5.51 Million USD | 7.14% |
| 2016 Q3 | 5.15 Million USD | 7.69% |
| 2015 Q1 | 640.99 Thousand USD | 3.71% |
| 2015 FY | 4.48 Million USD | 626.29% |
| 2015 Q4 | 4.48 Million USD | 11.39% |
| 2015 Q3 | 4.03 Million USD | 608.48% |
| 2015 Q2 | 568.82 Thousand USD | -11.26% |
| 2014 Q4 | 618.07 Thousand USD | -8.23% |
| 2014 Q1 | 680.91 Thousand USD | 1.61% |
| 2014 Q3 | 673.5 Thousand USD | 0.52% |
| 2014 FY | 618.07 Thousand USD | -7.77% |
| 2014 Q2 | 670.01 Thousand USD | -1.6% |
| 2013 Q3 | 660.02 Thousand USD | 0.88% |
| 2013 Q4 | 670.15 Thousand USD | 1.54% |
| 2013 Q1 | 658.86 Thousand USD | 1.09% |
| 2013 FY | 670.15 Thousand USD | 2.82% |
| 2013 Q2 | 654.28 Thousand USD | -0.69% |
| 2012 FY | 651.75 Thousand USD | -1.07% |
| 2012 Q4 | 651.75 Thousand USD | 0.0% |
| 2011 FY | 658.77 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -242.22% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -594.949% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 57.582% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 87.551% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -494.171% |
| Better Therapeutics, Inc. | 23.84 Million USD | 30.744% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -99.324% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -65.547% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 37.31% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 48.048% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 76.219% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -107.814% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 65.679% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 89.505% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -370.97% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 22.442% |
| Molecular Templates, Inc. | 31.17 Million USD | 47.028% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -31.939% |
| NexImmune, Inc. | 5.08 Million USD | -224.769% |
| Orgenesis Inc. | 35.53 Million USD | 53.533% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -6097.872% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -619.373% |
| Scopus BioPharma Inc. | 7.45 Million USD | -121.506% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 96.661% |
| Statera Biopharma, Inc. | 22.67 Million USD | 27.184% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -51.292% |
| Trevena, Inc. | 48.26 Million USD | 65.787% |
| Vaxxinity, Inc. | 30.94 Million USD | 46.639% |
| Vaccinex, Inc. | 5.94 Million USD | -177.886% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -738.881% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 56.97% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -497.923% |